Last updated: August 5, 2026
TIKOSYN, the branded dofetilide capsule, is an off-patent Class III antiarrhythmic with a commercially relevant excipient profile. The core formulation uses conventional solid-dose excipients: corn starch, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate. The principal opportunity is not brand preservation. It is development of reliable generic, differentiated, and supply-secure capsule products that meet strict bioequivalence and manufacturing requirements for a narrow-therapeutic-index cardiovascular drug.[1]
What is TIKOSYN and which excipients does it contain?
TIKOSYN contains dofetilide, a potassium-channel blocker approved for maintenance of normal sinus rhythm in patients with atrial fibrillation or atrial flutter. It is supplied as immediate-release hard gelatin capsules in 125 microgram, 250 microgram, and 500 microgram strengths.[1]
The marketed formulation uses the following capsule-fill excipients:
| Formulation component |
Function |
| Corn starch |
Diluent and disintegrant |
| Microcrystalline cellulose |
Diluent, compressibility aid, and structural filler |
| Sodium starch glycolate |
Superdisintegrant |
| Magnesium stearate |
Lubricant |
| Gelatin |
Capsule-shell material |
| Titanium dioxide and colorants |
Opacifier and capsule identification |
The exact capsule-shell colorant composition varies by strength and market presentation. Product-specific regulatory filings should rely on the current approved label and the applicable DailyMed record rather than historical secondary databases.[1,2]
TIKOSYN does not use an extended-release matrix, lipid vehicle, enteric coating, or complex delivery system. Its commercial formulation is a conventional immediate-release hard capsule.
How does the TIKOSYN excipient strategy affect product performance?
The formulation is designed for rapid capsule disintegration and reproducible dofetilide release. The combination of microcrystalline cellulose, corn starch, and sodium starch glycolate provides a conventional route to acceptable dissolution without reliance on specialized excipients.
The highest technical risks are dose uniformity, dissolution consistency, and excipient-driven changes in absorption. Dofetilide is administered at microgram-level doses, so small absolute deviations can produce material percentage changes in drug loading. The 125 microgram strength presents the greatest manufacturing challenge because the active ingredient represents a very small fraction of the capsule fill.
Dose uniformity and low-dose manufacturing
A generic manufacturer must control:
- Blend uniformity at low drug loading
- Segregation during transfer and encapsulation
- Loss of dofetilide to equipment surfaces
- Magnesium stearate mixing time
- Capsule-fill weight variation
- Assay and content uniformity across all three strengths
Direct blending may be operationally adequate, but a manufacturer may evaluate geometric dilution, ordered mixing, or a premix strategy to improve distribution. Any process change must preserve dissolution and bioequivalence.
Dissolution and disintegration
Sodium starch glycolate supports rapid disintegration, while magnesium stearate can retard wetting and dissolution if overmixed or used at excessive concentrations. A formulation with lower lubricant concentration or a controlled lubrication cycle could improve robustness, but the change would require comparative dissolution and regulatory justification.
For a generic product, excipient selection is therefore constrained by the need to match the reference product's release behavior. A theoretically superior formulation has limited value if it creates a bioequivalence risk.
Excipient compatibility
Dofetilide has a narrow dosing range and is administered under a structured initiation protocol. The formulation should be evaluated for:
- Moisture exposure
- Oxidative degradation
- Drug adsorption to processing equipment
- Interaction with capsule-shell materials
- Lubricant-related dissolution changes
- Colorant and shell stability
- Stability after repackaging into pharmacy containers
The core excipients are widely available and inexpensive. Their value is operational rather than proprietary.
What formulations are protected by TIKOSYN patents?
TIKOSYN's original commercial protection was associated with the dofetilide product and its regulatory exclusivity period, not with a complex modern formulation platform. The product was approved by the FDA in 1999 under NDA 020931.[1,3]
The principal commercial formulation is:
| Attribute |
TIKOSYN product |
| Active ingredient |
Dofetilide |
| Dosage form |
Immediate-release hard capsule |
| Strengths |
125, 250, and 500 micrograms |
| Route |
Oral |
| NDA |
020931 |
| Approval date |
October 1, 1999 |
| Current regulatory route for competitors |
Abbreviated New Drug Application |
| Biologic status |
Not applicable |
No biosimilar pathway applies because dofetilide is a small-molecule active pharmaceutical ingredient. Competitive products enter through abbreviated new drug applications, not abbreviated biologics applications.[3,4]
The original product is no longer protected by the type of market exclusivity that would prevent routine generic competition. FDA-approved generic dofetilide capsules are available in the United States.[4]
When does TIKOSYN lose exclusivity?
TIKOSYN has already lost practical market exclusivity. The relevant commercial opportunity is generic substitution and formulation competition, not future first generic entry.
| Protection category |
TIKOSYN status |
| New chemical entity exclusivity |
Expired |
| Orphan-drug exclusivity |
Not the principal commercial barrier for this product |
| Patent-based exclusivity |
No current brand-level barrier preventing approved generic competition |
| Generic availability |
Yes |
| Biosimilar competition |
Not applicable |
The Orange Book remains the controlling source for current listed patents, exclusivity codes, and approved generic products. The commercial status of TIKOSYN is consistent with a mature generic market rather than a protected branded product.[4]
How many patents cover TIKOSYN?
The practical answer is that no active patent estate currently prevents approved generic dofetilide capsule competition in the United States.
Patent analysis should distinguish among:
- Original compound patents
- Formulation patents
- Manufacturing patents
- Method-of-use patents
- Orange Book-listed patents
- Expired or unenforceable historical patents
For TIKOSYN, the commercially relevant question is Orange Book linkage. Generic applicants can file under Section 505(j), with Paragraph IV certification used only when an applicant challenges an unexpired listed patent. Because generic dofetilide capsules are already approved, the product is not dependent on a pending first Paragraph IV event to open the market.[3,4]
No current biosimilar patent risk applies.
Which companies are challenging TIKOSYN?
Competition is primarily from generic dofetilide manufacturers rather than branded challengers. FDA records identify approved dofetilide capsule products from multiple generic applicants or manufacturers over time.[4,5]
The principal competitive variables are:
- ANDA approval status
- Strength availability
- Manufacturing-site reliability
- Wholesale acquisition cost
- Pharmacy benefit substitution
- Hospital and cardiology-account access
- Ability to supply all three strengths
- Product discontinuation risk
Company-level market shares can change as suppliers enter or exit. The FDA Orange Book and commercial drug databases are the appropriate records for current applicant and marketing-status verification.[4]
What commercial opportunities exist in TIKOSYN excipients?
1. Generic capsule development
The clearest opportunity is a conventional generic product that matches the reference formulation closely while improving process control. A manufacturer can compete through reliable supply, low defect rates, and complete strength coverage.
A three-strength product is commercially stronger than a single-strength launch because dofetilide dosing is individualized and titrated according to renal function and QT response. Pharmacies and hospitals generally benefit from a supplier that can support the full strength range.
2. Excipient supply and dual sourcing
The formulation uses commodity excipients, but supply continuity remains commercially relevant. Suppliers can compete by offering:
- Low-bioburden corn starch
- Consistent particle-size microcrystalline cellulose
- Controlled-moisture sodium starch glycolate
- Pharmaceutical-grade magnesium stearate
- Capsule shells with validated colorant systems
- Dual-source qualification packages
The opportunity is strongest where a manufacturer needs a qualified second source without changing the qualitative and quantitative formulation profile.
3. Manufacturing-process licensing
A process package that improves low-dose blend uniformity could have value even without a patent. Potentially useful process assets include:
- Dofetilide premix technology
- Segregation-resistant transfer systems
- In-process near-infrared monitoring
- Automated capsule-weight rejection
- Small-batch containment and cleaning procedures
- Stability protocols for low-dose capsules
These assets can reduce batch failure and support contract manufacturing agreements.
4. Differentiated packaging
Dofetilide initiation requires inpatient monitoring, renal-function assessment, dose adjustment, and electrocardiographic observation. Packaging can support medication safety through:
- Strength-specific cartons
- Tall-man or color-coded labeling
- Hospital unit-dose packaging
- Electronic product identification
- Clear differentiation between 125, 250, and 500 microgram capsules
- Pharmacy-facing dispensing warnings
Packaging does not replace the FDA-required initiation protocol, but it can reduce selection errors between capsule strengths.[1]
5. Alternative dosage forms
Alternative oral dosage forms, including orally disintegrating tablets or liquid products, could address administration problems in selected patients. They would also create greater regulatory and clinical risk.
A liquid product would require control of:
- Dofetilide solubility
- Dose uniformity after shaking
- Container adsorption
- Preservative compatibility
- Photostability
- Measurement-device accuracy
- Stability after opening
Because dofetilide dosing is highly sensitive and the approved product is a capsule, an alternative dosage form would need a clear clinical or adherence advantage to justify development expense.
What generic entry risks exist for TIKOSYN?
Generic entry risk is already realized, but several risks affect the profitability of new entrants.
| Risk |
Commercial effect |
| Low drug dose |
Higher content-uniformity and process-control burden |
| Narrow therapeutic index concerns |
Greater scrutiny of bioequivalence and dissolution |
| Three strengths required |
Higher inventory and validation cost |
| Small market size relative to common cardiovascular drugs |
Limited scale economics |
| Hospital initiation requirements |
Concentrated account access |
| Commodity formulation |
Limited product differentiation |
| API supply constraints |
Potential margin erosion or stockouts |
| Capsule-strength confusion |
Packaging and medication-error exposure |
The product may be unattractive for a manufacturer seeking high-volume generic revenue. It is more suitable for a focused cardiovascular portfolio, contract manufacturer, or supplier with established low-dose encapsulation capability.
How strong is the TIKOSYN patent estate?
The patent estate is commercially weak as a barrier to generic entry. The product's value lies in established clinical use, regulatory familiarity, and physician knowledge rather than enforceable formulation exclusivity.
A strong new patent position would require a genuinely differentiated formulation or manufacturing invention, such as:
- A demonstrably improved low-dose uniformity process
- A stability-enhancing composition
- A clinically meaningful alternative dosage form
- A device or packaging system tied to a measurable safety benefit
Routine substitution of one standard diluent for another is unlikely to create a durable, commercially meaningful patent position without unexpected technical results.
What patent litigation and settlement agreements affect TIKOSYN?
The commercial record does not indicate that current TIKOSYN access depends on a live patent litigation settlement. Generic dofetilide is already marketed, and the product is not in a pre-generic-entry litigation posture.
Any historical Paragraph IV litigation or settlement should be evaluated against the relevant patent's expiration, Orange Book listing, and the generic product's actual approval date. Historical litigation has limited impact on present-day excipient strategy unless it produced enforceable restrictions on a specific formulation or manufacturing process.
What is the FDA regulatory status of TIKOSYN?
TIKOSYN is FDA-approved for maintenance of normal sinus rhythm in specified patients with atrial fibrillation or atrial flutter. Initiation or re-initiation requires hospitalization with continuous electrocardiographic monitoring because dofetilide can prolong the QT interval and cause torsades de pointes.[1]
This safety requirement affects commercial strategy. A manufacturer is selling into a specialized prescribing and dispensing environment, not a routine self-administered chronic-treatment market.
Key Takeaways
- TIKOSYN contains dofetilide in immediate-release hard gelatin capsules at 125, 250, and 500 micrograms.
- The core excipients are conventional and include corn starch, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate.
- TIKOSYN is off-patent in practical commercial terms, and generic dofetilide capsules are available.
- No biosimilar pathway applies.
- The strongest opportunity is a reliable three-strength generic supported by robust low-dose blend uniformity and dissolution control.
- Excipient suppliers can compete through dual sourcing, particle-size control, moisture control, and regulatory documentation.
- Alternative formulations face substantial bioequivalence, stability, and medication-safety hurdles.
- Commercial differentiation is more likely to come from manufacturing reliability, packaging, and supply continuity than from ordinary excipient substitution.
FAQs
Is dofetilide a narrow-therapeutic-index drug?
Dofetilide requires careful dose selection and inpatient initiation because excessive exposure can prolong the QT interval. Manufacturers should treat low-dose uniformity and dissolution control as high-priority quality attributes.
Can a company patent a new TIKOSYN excipient formulation?
Yes, but routine excipient substitution is unlikely to support a strong patent position. A candidate formulation would need novelty, non-obviousness, and evidence of an unexpected technical or clinical benefit.
Does TIKOSYN require a special capsule shell?
The product uses hard gelatin capsules with strength-specific color and marking systems. A generic manufacturer can use a different shell configuration if it meets regulatory, stability, identification, and bioequivalence requirements.
Is a liquid dofetilide product commercially attractive?
It could address administration needs, but the development burden is high. Solubility, dose measurement, stability, adsorption, and clinical equivalence would need to be controlled.
What is the main commercial risk for a new generic dofetilide entrant?
The main risk is limited market scale relative to the manufacturing and regulatory burden of supporting three microgram strengths under a safety-sensitive dosing regimen.
References
-
U.S. Food and Drug Administration. (2023). Tikosyn (dofetilide) prescribing information. Pfizer Laboratories.
-
National Library of Medicine. (2024). DailyMed: Tikosyn-dofetilide capsule. U.S. National Library of Medicine.
-
U.S. Food and Drug Administration. (1999). FDA approves Tikosyn (dofetilide) for atrial fibrillation and atrial flutter. Center for Drug Evaluation and Research.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. U.S. Department of Health and Human Services.
